Chardan Capital Begins Coverage on Senti Biosciences (NASDAQ:SNTI)

Chardan Capital began coverage on shares of Senti Biosciences (NASDAQ:SNTIGet Rating) in a research report released on Thursday morning, The Fly reports. The brokerage issued a buy rating on the stock.

Senti Biosciences Price Performance

Shares of NASDAQ:SNTI opened at $1.40 on Thursday. Senti Biosciences has a 1-year low of $1.31 and a 1-year high of $10.35. The stock’s 50-day moving average price is $2.04.

Senti Biosciences (NASDAQ:SNTIGet Rating) last announced its quarterly earnings results on Monday, August 15th. The company reported ($0.86) EPS for the quarter. The firm had revenue of $1.36 million during the quarter.

Hedge Funds Weigh In On Senti Biosciences

A number of large investors have recently bought and sold shares of SNTI. Allen Operations LLC acquired a new position in Senti Biosciences during the 2nd quarter worth approximately $42,000. Virtu Financial LLC acquired a new position in Senti Biosciences during the 2nd quarter worth approximately $43,000. Millennium Management LLC acquired a new position in Senti Biosciences during the 2nd quarter worth approximately $71,000. TD Asset Management Inc. acquired a new position in Senti Biosciences during the 2nd quarter worth approximately $172,000. Finally, Kingfisher Capital LLC bought a new stake in shares of Senti Biosciences during the 2nd quarter worth approximately $222,000. Institutional investors and hedge funds own 42.81% of the company’s stock.

Senti Biosciences Company Profile

(Get Rating)

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

Featured Stories

The Fly logo

Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.